Type 2 Diabetes MellitusGIANTNCT00499824
GIANT: General Practitioner Implementation in Asia of Normoglycaemic Targets
A study testing Education of general practitioners on the IDF-WPR guidelines in people with Type 2 Diabetes Mellitus, run by International Diabetes Institute, Australia at 10 sites in 9 countries.
Trial summary
To test whether the International Diabetes Federation - Western Pacific Region (IDF-WPR) Guidelines are more effective than standard practices in primary care (general practitioner) clinics for the management of type 2 diabetes mellitus (T2DM) in Asia. Read more about this study
- Who is it for?
- Ages 30 to 75 years
- Conditions the study is for
- Type 2 Diabetes Mellitus
- What is being tested?
- Education of general practitioners on the IDF-WPR guidelines
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 386 participants
- Where
- 10 sitesin 9 countries
- Study dates
- Jan 2007to Feb 2009
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 30 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Men or women who are 30 to 75 years of age (inclusive) at Study Visit 1.
- Clinical diagnosis of type 2 diabetes (defined according to IDF Guidelines) for a minimum of 6 months prior to Study Visit 1
- Patients for whom the GP is the primary medical provider of diabetes care and for whom referral to another doctor for diabetes care is not anticipated within 3 months of Study Visit 1
- Patients who give informed consent to participate.
Who cannot join
- Patients with type 1 diabetes mellitus
- Patients with any previous episode of ketoacidosis
- Patients who required chronic use (>/= 6 months) of insulin at any time in the past, with the exception of females during pregnancy
- Patients receiving insulin treatment at Study Visit 1 or within the previous 6 months, with the exception of patients who received short-term treatment (= 7 days) with insulin to maintain glycaemic control for an acute event (e.g. hospitalisation or medical procedure/intervention, infection or trauma).
- Treatment with glucocorticoid at Study Visit 1 or within the previous 6 months, with the exception of topical or inhaled glucocorticoid
- Females who are pregnant or considering pregnancy or stopping contraception within the course of the study
Show all 10Show fewer
- Patients with end-stage renal disease, defined as glomerular filtration rate (GFR) by the MDRD (Modification of Diet in Renal Disease) formula < 15 ml/min/1.73 m2, or on renal replacement therapy with haemodialysis, peritoneal dialysis or renal transplant.
- Patients with psychiatric disease, active drug or alcohol abuse or other cognitive impairment that may interfere with treatment compliance.
- Receipt of any investigational drug within 30 days of Study Visit 1.
- Patients receiving diabetes care from another doctor (specialist endocrinologist, general physician, or another GP) Other eligibility criteria considerations The HbA1c at entry for newly recruited patients will be monitored centrally. If there is a significant risk that more than 25% of the total study population will have a baseline HbA1c </= 6.5%, then recruitment of subsequent patients will be restricted to those with HbA1c > 6.5%.
Trial locations and contacts
10 sites in 9 countries.
10 sites in 9 countries
China2 sites
Department of Endocrinology & Metabolism, Peking University People's Hospital
Beijing, 100044
Department of Medicine & Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong
Shatin, Hong Kong
Indonesia1 site
Diabetes and Nutrition Center, Dr. Soetomo Teaching Hospital - Airlangga University,
Surabaya, 60286
Malaysia1 site
School of Medicine and Health Sciences, Monash University House
Johor Bahru, 80100
Philippines1 site
Section of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of the Philippines College of Medicine
Manila
Singapore1 site
Diabetes, Lipid and Endocrine Practice, Gleneagles Medical Centre
Singapore, 258499
South Korea1 site
Department of Endocrinology & Metabolism, Kangnam St. Mary's Hospital, The Catholic University of Medicine
Seoul
Taiwan1 site
Dept of Medical Research and Education, Taipei Veterans General Hospital,
Taipei
Thailand1 site
Diabetes and Endocrinology Unit, Department of Medicine, Rajavithi Hospital,
Bangkok, 10400
About this study
To test whether the International Diabetes Federation - Western Pacific Region (IDF-WPR) Guidelines are more effective than standard practices in primary care (general practitioner) clinics for the management of type 2 diabetes mellitus (T2DM) in Asia. A 12-month multinational multicentre prospective cluster randomisation clinical trial within a primary care setting, with 2 parallel treatment arms: diabetes management using IDF-WPR guidelines versus standard clinic practices. 400 subjects will be recruited from 100 sites (4 subjects per site) in ten Asian countries (China, Hong Kong, Indonesia, Korea, Malaysia, Philippines, Singapore, Taiwan, Thailand and Vietnam).
Read the detailed description
Description of intervention(s) / exposure and control treatment: This is a prospective multinational, multicentre, cluster-randomised study conducted within the primary care setting, with two parallel treatment arms: standard clinical practice versus education on diabetes management using International Diabetes Federation - Western Pacific Region (IDF-WPR) "Type 2 diabetes practical targets and treatments". The study duration will be 12 months.
100 General Practitioners (GPs) (10 per country) will be randomised to receive education on the IDF-WPR guidelines or to receive no trial-related education.
- GPs in both groups will be required to recruit 4 of their own patients meeting the eligibility criteria. The complete entry criteria are detailed in a following section.
- GPs in both groups will manage the recruited patients according to their own clinical judgement. Frequency of patient visits to the GP's clinic will be determined by the GP. All medication prescribed by the GPs should already be registered in the participating countries.
- Blood sampling of patients will be required at Study Visit 1 (Screening/Baseline), Study Visit 2 (month 6) and Study Visit 3 (month 12).
The intervention will comprise an educational program on the guidelines for GPs, and will be carried out by the national coordinating centre in each country, based on a template provided by the international coordinating centre (International Diabetes Institute, Australia). The educational program for the GPs randomised to the intervention arm will:
- Combine didactic and interactive sessions.
- Involve opinion leaders, i.e. the national lead investigator
- Aim to resolve barriers to practical implementation of guidelines already identified from previous studies (e.g. discuss starting insulin)
- Present the evidence for the guidelines.
- Highlight any conflicts between the guidelines and local prescribing regulations, and confirm the need to follow the local prescribing regulations in these instances
- Involve an initial educational symposium and a follow-up continuing medical education symposium at 3 months
Organisational changes to improve guideline adherence for the study will include:
- Paper or electronic reminders of the guidelines will be sent to GPs every 3 months.
- Desktop reminders cards with key guideline algorithms.
- Insertion of a flowsheet (diabetes action plan) into the patient's medical notes by the study nurse (at the time of review of the practitioner's baseline HbA1c utilisation).
Patient-centred approaches to improve guideline adherence for the study will include:
- Encouragement and empowerment of patients to ask questions of the treating practitioners
- Provision of each patient with a "diabetes passport" to be held by the patient, to encourage discussion between the patient and practitioner and also recording of results of medical examinations. This will be provided at the baseline visit to the national coordinating centre.
- Conditions
- Type 2 Diabetes Mellitus
- Being tested
- Education of general practitioners on the IDF-WPR guidelines
- Keywords
- Diabetes, Management guidelines, Efficacy
- Medical subject headings
- Diabetes Mellitus, Type 2, Diabetes Mellitus
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Education of general practitioners on the IDF-WPR guidelinesBehavioural
The intervention will comprise an educational program on the guidelines for GPs, and will be carried out by the national coordinating centre in each country, based on a template provided by the international coordinating centre (International Diabetes Institute, Australia). This will involve:
an initial educational symposium and a follow-up continuing medical education symposium at 3 months; paper or electronic reminders of the guidelines sent to GPs every 3 months; desktop reminder cards with guideline algorithms; insertion of a flowsheet (diabetes action plan) into the patient's medical notes by the study nurse; provision of each patient with a "diabetes passport" to be held by the patient.
| Study group | Role | What they receive |
|---|---|---|
| 1 | Experimental | Medical Practitioners who receive education on diabetes management following the guidelines of the International Diabetes Federation Western Pacific Region Receives: Behavioral: Education of general practitioners on the IDF-WPR guidelines |
| 2 | No intervention | Medical practitioners who follow standard practice for management of their patients with type 2 diabetes |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in HbA1c from baseline in subjects with baseline HbA1c >/=6.5%
Measured: 6 months
Secondary outcomes (1)
HbA1c, FPG, BP, lipids; hypoglycemic events; health care use; number of GP HbA1c measurements; number of treatment escalations; adverse events; barriers to guideline implementation; determine if study patients are representative of GP's diabetic practice
Measured: 6 & 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Jul 2007 (estimated)
- Study startJan 2007
- Primary completionJan 2009
- Study completionFeb 2009
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Type 2 Diabetes MellitusStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 386 participants (actual)
Sponsor and investigators
- Lead sponsor
- International Diabetes Institute, Australia
- Sponsor type
- University, hospital or other
- Collaborators
- GlaxoSmithKline
- Investigators
- Jonathan E Shaw, MD MRCP FRACP, Principal investigator, International Diabetes Institute, Australia
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00499824
- Sponsor's protocol ID
- IDI Project 4/2006
- Acronym
- GIANT
- Status last verified
- May 2010
- First submitted
- 9 Jul 2007
- Last updated
- 4 May 2010
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 4 May 2010. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- GIANT: General Practitioner Implementation in Asia of Normoglycaemic Targets
- ClinicalTrials.gov ID
- NCT00499824
- Acronym / sponsor ID
- GIANT / IDI Project 4/2006
- Conditions
- Type 2 Diabetes Mellitus
- Keywords
- Diabetes, Management guidelines, Efficacy
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 386 participants (actual)
- Lead sponsor
- International Diabetes Institute, AustraliaUniversity, hospital or other
- Collaborators
- GlaxoSmithKline
- Study start
- Jan 2007
- Primary completion
- Jan 2009 (actual)
- Study completion
- Feb 2009 (actual)
- First posted
- 11 Jul 2007 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To test whether the International Diabetes Federation - Western Pacific Region (IDF-WPR) Guidelines are more effective than standard practices in primary care (general practitioner) clinics for the management of type 2 diabetes mellitus (T2DM) in Asia. A 12-month multinational multicentre prospective cluster randomisation clinical trial within a primary care setting, with 2 parallel treatment arms: diabetes management using IDF-WPR guidelines versus standard clinic practices. 400 subjects will be recruited from 100 sites (4 subjects per site) in ten Asian countries (China, Hong Kong, Indonesia, Korea, Malaysia, Philippines, Singapore, Taiwan, Thailand and Vietnam).
Detailed description
Description of intervention(s) / exposure and control treatment: This is a prospective multinational, multicentre, cluster-randomised study conducted within the primary care setting, with two parallel treatment arms: standard clinical practice versus education on diabetes management using International Diabetes Federation - Western Pacific Region (IDF-WPR) "Type 2 diabetes practical targets and treatments". The study duration will be 12 months.
100 General Practitioners (GPs) (10 per country) will be randomised to receive education on the IDF-WPR guidelines or to receive no trial-related education.
- GPs in both groups will be required to recruit 4 of their own patients meeting the eligibility criteria. The complete entry criteria are detailed in a following section.
- GPs in both groups will manage the recruited patients according to their own clinical judgement. Frequency of patient visits to the GP's clinic will be determined by the GP. All medication prescribed by the GPs should already be registered in the participating countries.
- Blood sampling of patients will be required at Study Visit 1 (Screening/Baseline), Study Visit 2 (month 6) and Study Visit 3 (month 12).
The intervention will comprise an educational program on the guidelines for GPs, and will be carried out by the national coordinating centre in each country, based on a template provided by the international coordinating centre (International Diabetes Institute, Australia). The educational program for the GPs randomised to the intervention arm will:
- Combine didactic and interactive sessions.
- Involve opinion leaders, i.e. the national lead investigator
- Aim to resolve barriers to practical implementation of guidelines already identified from previous studies (e.g. discuss starting insulin)
- Present the evidence for the guidelines.
- Highlight any conflicts between the guidelines and local prescribing regulations, and confirm the need to follow the local prescribing regulations in these instances
- Involve an initial educational symposium and a follow-up continuing medical education symposium at 3 months
Organisational changes to improve guideline adherence for the study will include:
- Paper or electronic reminders of the guidelines will be sent to GPs every 3 months.
- Desktop reminders cards with key guideline algorithms.
- Insertion of a flowsheet (diabetes action plan) into the patient's medical notes by the study nurse (at the time of review of the practitioner's baseline HbA1c utilisation).
Patient-centred approaches to improve guideline adherence for the study will include:
- Encouragement and empowerment of patients to ask questions of the treating practitioners
- Provision of each patient with a "diabetes passport" to be held by the patient, to encourage discussion between the patient and practitioner and also recording of results of medical examinations. This will be provided at the baseline visit to the national coordinating centre.
Study design
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| 1 | Experimental | Behavioral: Education of general practitioners on the IDF-WPR guidelinesMedical Practitioners who receive education on diabetes management following the guidelines of the International Diabetes Federation Western Pacific Region |
| 2 | No intervention | –Medical practitioners who follow standard practice for management of their patients with type 2 diabetes |
Who may qualify
- Ages
- 30 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Men or women who are 30 to 75 years of age (inclusive) at Study Visit 1.
- Clinical diagnosis of type 2 diabetes (defined according to IDF Guidelines) for a minimum of 6 months prior to Study Visit 1
- Patients for whom the GP is the primary medical provider of diabetes care and for whom referral to another doctor for diabetes care is not anticipated within 3 months of Study Visit 1
- Patients who give informed consent to participate.
Key exclusion criteria (10 listed)
- Patients with type 1 diabetes mellitus
- Patients with any previous episode of ketoacidosis
- Patients who required chronic use (>/= 6 months) of insulin at any time in the past, with the exception of females during pregnancy
- Patients receiving insulin treatment at Study Visit 1 or within the previous 6 months, with the exception of patients who received short-term treatment (= 7 days) with insulin to maintain glycaemic control for an acute event (e.g. hospitalisation or medical procedure/intervention, infection or trauma).
- Treatment with glucocorticoid at Study Visit 1 or within the previous 6 months, with the exception of topical or inhaled glucocorticoid
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Education of general practitioners on the IDF-WPR guidelinesThe intervention will comprise an educational program on the guidelines for GPs, and will be carried out by the national coordinating centre in each country, based on a template provided by the international coordinating centre (International Diabetes Institute, Australia). This will involve: an initial educational symposium and a follow-up continuing medical education symposium at 3 months; paper or electronic reminders of the guidelines sent to GPs every 3 months; desktop reminder cards with guideline algorithms; insertion of a flowsheet (diabetes action plan) into the patient's medical notes by the study nurse; provision of each patient with a "diabetes passport" to be held by the patient. | Behavioural | 1 |
Primary outcome
Change in HbA1c from baseline in subjects with baseline HbA1c >/=6.5%
Time frame: 6 months
1 secondary outcome
HbA1c, FPG, BP, lipids; hypoglycemic events; health care use; number of GP HbA1c measurements; number of treatment escalations; adverse events; barriers to guideline implementation; determine if study patients are representative of GP's diabetic practice
Time frame: 6 & 12 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 May 2010.
Related trials for Type 2 Diabetes Mellitus
Not yet recruitingPhase 3
Efficacy and Safety of Once-Weekly SHR-3167 Compared With Once-Daily Insulin Glargine in Adults With Insulin-Naive Type 2 Diabetes
Type 2 Diabetes
Active, not recruiting
Digital Reinforcement of Motivational Interviewing Micro-Skills Among Primary Care Healthcare Professionals
Hypertension (Without Type 2 Diabetes Mellitus)
Recruiting
Investigating Vascular Properties of HEMI and SPG Signals in Individuals With or at Risk for Chronic Kidney Disease
Chronic Kidney Disease, Hypertension (HTN)
Not yet recruitingPhase 3
A Study to Evaluate the Effectiveness and Safety of the Drug AZD6234 for Managing Weight in Adults Who Are Obese or Overweight. These Participants May or May Not Also Have Type 2 Diabetes
Obesity, Overweight
Not yet recruiting
Impact of Endoscopic Sleeve Gastroplasty (ESG) in Obese Adults With Type 2 Diabetes (T2D)
Type 2 Diabetes Mellitus (T2D), Obesity (BMI>30)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Jonathan E Shaw, MD MRCP FRACP principal investigator
International Diabetes Institute, Australia
10 sites in 9 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Education of general practitioners on the IDF-WPR guidelines in people with Type 2 Diabetes Mellitus, run by International Diabetes Institute, Australia at 10 sites in 9 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 4 May 2010. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 10 sites in China, Indonesia, Malaysia, Philippines, Singapore and 4 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in HbA1c from baseline in subjects with baseline HbA1c >/=6.5% (time frame: 6 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 May 2010.